retatrutide safety trial results Results: 28.3% Weight Loss Data ⚠️ BEWARE OF RETATRUTIDE SOLD
Description
This is not a GLP-1 receptor agonist
One-and-done behavior is especially common among obesity patients, as 19% of obesity GLP-1 users fill only a single prescription
2 (T2D) , GLP-1R, GIPR, GCGR cAMP, Arrestin, Internalization
Fast forward to today, and that commitment is stronger than ever
They see bone loss as the primary risk
